New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
09:21 EDTKATE, SUPN, TIPT, FRF, TCAP, HCLP, FLO, CALL, SOL, NOAH, EXAS, DNDN, CNAT, ICPT, ANF, INSYOn The Fly: Pre-market Movers
HIGHER: Intercept (ICPT), up 46% after upgraded at Leerink and Citigroup following OCA data. Conatus Pharmaceuticals (CNAT), which also develops treatments for liver disease, up 8.5%... Fontegra Financial (FRF), up 40% after Tiptree Financial (TIPT) to acquire the company for $10.00 per share in cash... Insys Therapeutics (INSY), up 15.4% after submiting NDA for new formula of Dronabinol Oral Solution, saying it is on track to submit at least four IND applications with the FDA in the second half of 2014... Exact Sciences (EXAS), up 8% after announcing FDA approved for Cologuard... Abercrombie & Fitch (ANF), up 2.7% after upgraded at Stifel. UP AFTER EARNINGS: Kate Spade (KATE), up 5.5%... Noah Holdings (NOAH), up 3%... ReneSola (SOL), up 5%... Supernus (SUPN), up 14%. LOWER: NII Holdings (NIHD), down 54.5% after warning it needs to make "key decisions" to address liquidity, "likely" to file a voluntary petition for relief under Chapter 11 of the Bankruptcy Code... Dendreon (DNDN), down 23.6% after warning that its alternatives could leave shareholders with no ownership... magicJack (CALL), down 10.3%, downgraded at Canaccord following Q2 results... Hi-Crush Partners (HCLP), down 4.7% after filing to sell 3.26M common units representing limited partners... Triangle Capital (TCAP), down 3.8% after filing to sell 4M shares of common stock. DOWN AFTER EARNINGS: Nuance (NUAN), down 9.4%... Flowers Foods (FLO), down 7.8%.
News For KATE;ANF;ICPT;CNAT;DNDN;EXAS;NOAH;SOL;CALL;FLO;HCLP;TCAP;FRF;TIPT;SUPN;INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 10, 2014
11:18 EDTEXASOptions with decreasing implied volatility
Subscribe for More Information
11:05 EDTEXASExact Sciences jumps after CMS agrees to cover cancer test
Subscribe for More Information
09:00 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
07:50 EDTEXASExact Sciences to see significant short squeeze on CMS decision, says Canaccord
Subscribe for More Information
07:32 EDTEXASExact Sciences price target raised to $27 from $20 at Jefferies
Subscribe for More Information
07:16 EDTEXASExact Sciences CMS decision a 'major positive' for shares, says Mizuho
Subscribe for More Information
07:12 EDTEXASExact Sciences price target raised to $34 from $28 at JMP Securities
JMP Securities increased its price target on Exact Sciences after CMS stated that the company's colorectal screening tool would be covered by Medicare and granted the company's request to price the test at $502. The firm thinks Cologuard will become the standard of care for the detection of colorectal cancer. It reiterates an Outperform rating on the stock. .
October 9, 2014
18:47 EDTEXASOn The Fly: After Hours Movers
UP AFTER EARNINGS: Helen of Troy (HELE), up 3%... Barracuda Networks (CUDA), up marginally after reporting second quarter results. ALSO HIGHER: Sucampo Pharmaceuticals (SCMP), up 19.2% after announcing settlement agreement resolving patent litigation on AMITIZA... Civeo (CVEO), up 15% after Greenlight Capital reported a 9.99% stake in the company... EXCO Resources (XCO), up 10.6% after T. Boone Pickens says that company approached by buyers, reported by Bloomberg... EXACT Sciences (EXAS), up 3.7% after announcing final national coverage determination for Cologuard... US Ecology (ECOL), up 2.5% following announcement that it will replace Measurement Specialties (MEAS) in S&P 600. DOWN AFTER EARNINGS: Procera Networks (PKT), down 19.3%... Sizmek (SZMK), down 13.9% following third quarter revenue guidance... VOXX International (VOXX), down 12.5%... Knowles (KN), down 8.1% after lowering third quarter guidance... Microchip (MCHP), down 8.2% after lowering second quarter guidance... Juniper Networks (JNPR), down 3.6% after lowering third quarter outlook. ALSO LOWER: GT Advanced Technologies (GTAT), down 23.3% following a Bloomberg report that it will as to wind down sapphire operations.
18:20 EDTEXASExact Sciences announces final national coverage determination for Cologuard
Subscribe for More Information
16:34 EDTHCLPHi-Crush announces volume increase to purchase agreement with Halliburton
Subscribe for More Information
10:50 EDTANFGap falls after announcing CEO Murphy will step down, weak September sales
Subscribe for More Information
09:41 EDTANFBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
09:03 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
08:22 EDTHCLPBofA/Merrill said weakness in frac sand stocks overdone
Subscribe for More Information
October 8, 2014
16:37 EDTTIPTTiptree Financial subsidiary announces $30.8M joint venture transaction
Subscribe for More Information
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
10:03 EDTCNATConatus announces acceptance for AASLD abstract
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use